= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Melnikov

MSACL 2018 EU Abstract

Topic: Metabolomics

Podium Presentation in the Ether on Thursday at 9:00 (Chair: Oleg Mayboroda)

Metabolomic Analysis of Changes in the Serum of Diabetic Patients Caused by Ulcers

Arsenty Melnikov (Presenter)
Internatrional Tomography Center SB RAS

Presenter Bio(s): Arsenty Melnikov is currently an undergraduate student at Physics Department of the Novosibirsk State University (Novosibirsk, Russia). He is working at the ITC SB RAS (Novosibirsk, Russia) in the fields of metabolomics, mass-spectrometry and data analysis since 2016. He is experienced in high-resolution LC-MS techniques and up-to-date statistical methods of data analysis. He is highly skilled in application of programming languages including Python and R for statistical analysis and has experience in univariate and multivariate statistical approaches for metabolomics, such as PCA, PLS-DA, OPLS-DA, SVM-RFE.
Current research interest is mainly devoted to applications of metabolomics in analysis of human diseases, especially diabetes and its application.

Authors: Arsenty Melnikov (1,2), Vadim Yanshole (1,2)
(1) International Tomography Center SB RAS, (2) Novosibirsk State University

Abstract

Patients with diabetes mellitus have approximately a 20% risk of developing an ulcer, 7% cases of which leads to an amputation. Despite widespread occurrence of diabetic ulcers, this complication is poorly studied, making this disease a topical object of study.

Current report provides the data on metabolomics changes in the serum of diabetic patients without complications as compared to the serum of diabetic patients with ulcers. More than 200 metabolites were detected with the use of two independent HPLC-MS method (HILIC and RPLC). The concentrations of several metabolites are found to differ significantly: phospholipids, bilirubin, 1,5–anhydroglucitol, oleamide.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no